Comparative study of aminosidine, etophamide and nimorazole, alone or in combination, in the treatment of intestinal amoebiasis in Kenya
- 49 Downloads
- 4 Citations
Summary
417 patients suffering from intestinal amoebiasis were randomly allocated to 6 different treatment groups in a controlled study in 3 District Hospitals in Kenya. The patients received either aminosidine (A), etophamide (E), nimorazole (N), or the combinations NA, NE, EA. Treatment in all cases was given twice daily for 5 days. Before and after treatment, rectosigmoidoscopy was done in each patient, and stool examination with characterization of invasive (IF) and non invasive (NIF) forms of amoeba was done daily throughout treatment, and on Days 15, 30 and 60 of follow-up.
Clinical cure was good after all the treatments, varying from 90 to 100%; parasitological cure at the end of treatment was 100% in the NA and EA treatments groups, and 98% in A group. The incidence of relapses was nil in the EA group, followed by 3% in NA and 6% in A groups. Anatomical cure (healing of ulcers) was 97.8% in the NA group, 95.5% in the N group and 88.5% in the A group. Drug tolerance was excellent or good after all the treatments, except that the EA combination produced diarrhoea in 76.5% of patients.
Overall analysis of the findings, including tolerance of the various treatments, showed that aminosidine either alone or in combination with nimorazole gave the best results.
Ulcers seen on rectosigmoidoscopy were more common in patients excreting invasive forms of amoebae in their stools.
Key words
Intestinal Amoebiasis Aminosidine Etophamide Nimorazole Drug combinations adverse effectsPreview
Unable to display preview. Download preview PDF.
References
- 1.W.H.O. Expert Committee (1987) Public health significance of intestinal parasitic infections. Bull WHO 65: 575–588Google Scholar
- 2.Iseki M, Nayashi K, Arap Siongok TK, Gatica SM (1983) Survey of the prevalence of intestinal protozoa in Naivasha, Kitni, Machakos, Tavata and Nandi hills areas in Kenya. Proc 2nd Ann Med Sci Conf, Nairobi, pp 197–199Google Scholar
- 3.W.H.O (1981) Intestinal protozoan and helmintic infections. Report of a WHO Scientific Group. Tech Rep Ser No 666, GenevaGoogle Scholar
- 4.Woodruff AW, Bell S (1969) The evaluation of amoebicides. Trans Roy Soc Trop Med Hyg 61: 435–440Google Scholar
- 5.Knight R (1980) The chemotherapy of amoebiasis. J Antimicrob Chemother 6: 577–593Google Scholar
- 6.Merrit RJ, Coughlin E, Thomas DW, Jariwala L, Swanson V, Sinatra FR (1982) Spectrum of Amebiasis in children. Am J Dis Child 136: 785–789Google Scholar
- 7.Ravdin JI (1987) Diagnosis and Management of Entamoeba histolytica infection. Infect Med 2: 28–34Google Scholar
- 8.Healy GR (1971) Laboratory diagnosis of amoebiasis. Bull NY Acad Med 47: 478–493Google Scholar
- 9.Anonymous (1985) Amoebiasis and its control — A WHO meeting. Bull WHO 63: 417–426Google Scholar
- 10.Powell SJ (1969) Drug trials in amoebiasis. Bull WHO 40: 956–958Google Scholar
- 11.El Sheikh A (1960) Paromomycin in the treatment of intestinal amoebiasis. AM & CT 7: 681–684Google Scholar
- 12.Biagi F, Alvarez R, Gonzales C (1974) Antiamebic action of etophamide in children. Trans Roy Soc Trop Med Hyg 68: 368–369Google Scholar
- 13.Sargeaunt PG, Williams JE, Green JD (1978) The differentiation of invasive and non-invasive Entamoeba histolytica by isoenzyme electrophoresis. Trans Roy Soc Trop Med Hyg 72: 519–521Google Scholar
- 14.Sargeaunt PG, Baveja UK, Nanda R, Anand BS (1984) Influence of geographical factors in the distribution of pathogenic zymodemes of Entamoeba histolytica: identification of zymodeme XIV in India. Trans Roy Soc Trop Med Hyg 78: 96–101Google Scholar
- 15.Rée GH (1984) Amoebiasis. Postgrad Doctor Asia 4: 176–179Google Scholar
- 16.Jackson TFHG, Gathiram V (1984) Seroepidemiological study of antibody responses to the zymodemes of Entamoeba histolytica. Lancet I: 716–718Google Scholar
- 17.Bottone EY (1984) Yersinia enterocolitica. In: Ellner PD (ed) Infectious diarrheal diseases. Current concepts and laboratory procedures. Dekker, New York, pp 13–48Google Scholar
- 18.Blaser MJ (1984) Campylobacter enteritis. In: Ellner PD (ed) Infectious diarrheal diseases, Current concepts and laboratory procedures. Dekker, New York, pp 1–12Google Scholar
- 19.Manson-Bahr PEC, Apted FIC (1982) Shigellosis and diarrhoea. In: Manson's tropical diseases. Balliere Tindall, London, pp 372–377Google Scholar
- 20.Krogstad DJ (1985) Amebiasis. In: Wingaarden JB, Smith LH Jr (eds) Cecils textbook of medicine, 17th ed. Saunders, London, pp 1799–1801Google Scholar
- 21.Wolfe MS (1982) The treatment of intestinal protozoan infections. Med Clin N Am 66: 707–720Google Scholar
- 22.Martinez-Palomo A (1982) The biology of Entamoeba histolytica. Research Studies Press, Chichester 1982, pp 105–107Google Scholar
- 23.Mitchison DA (1979) Basic mechanism of chemotherapy. Chest [Suppl] 76: 771–781Google Scholar
- 24.Bonadonna G (1988) Principles of cell proliferation. In: Bonadonna G, Robustelli della Cuna G (eds) Handbook of medical oncology. Masson, Milano, pp 13–20Google Scholar
- 25.Daikos GK, Kontomichalou P, Petassis E, Bilasis D (1963) Clinical and laboratory experience with aminosidine, a broad-spectrum oligosaccharide. Antimicrob Ag Chemother 3: 765–773Google Scholar
- 26.De Carneri I, Carnevali C (1978) Achievements and obstacles in research for new antiamoebic drugs. Arch Invest Med (Mex) 9 [Suppl 1]: 381–386Google Scholar
- 27.Camacho Gomez Daza M (1973) Valoracion de la nitrimidazina en el tratamiento de la amibiasis. Prensa Med Mex 38: 145–147Google Scholar
- 28.Ruiz Moreno F, Ruiz Healy F (1974) La etofamida nuevo quimioterapico para et tratamiento de la colopatia cronica amibiana por Entamoeba histolytica. Acta Latino-Am Protocol 16: 53–58Google Scholar